

> Return address PO Box 320, 1110 AH Diemen

To the Minister of Health, Welfare and Sport
PO Box 20350
2500 EJ THE HAGUE

**National Health Care
Institute**
Care
Medicinal Products

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl
T +31 (0)20 797 85 55

2022048924

Date 1 March 2023
Re: Advice on the clustering of combination products and ghost clusters in
GVS (part 4)

Our reference
2022048924

Dear Mr Kuipers,

In your letter of 12 May 2020, your predecessor asked the National Health Care Institute to produce an advisory report about clustering combination products and ghost clusters in the Medicine Reimbursement System, GVS (your reference 1681288-204715-GMT). For this analysis, the National Health Care Institute uses the overviews from the G-standard that were provided at your request by the Dutch Central Information Unit on Health Care Professions (CIBG)/Farmatec. Because this covers a large number of medicinal products, we have to make our recommendations in stages and in parts.

The first part of our advisory report was issued to you on 4 May 2021 (our reference 2021012702).¹ On 13 April 2022, the second part of this feasibility study was issued to you (our reference 2021044712).² For the fixed combination of cholecalciferol/calcium, the National Health Care Institute issued a separate package advice to you on 9 May 2022 (our reference 2021047270).³ On 13 July 2022, the National Health Care Institute issued the third part of this feasibility study to you (our reference 2022020138).⁴ This concluded the advisory report on the cluster classification of all combination products. A group of ghost products remains. This advice will be implemented in phases, as previously indicated. After issuing this advisory report (Part 4), the National Health Care Institute completed its recommendations about the clustering of all five injections.

Advisory reports for ghost drug injections (part 4)

In this advisory report, the National Health Care Institute assesses two insulin preparations (*Insuman® Infusat* and *Insulatard®*) and three parenteral administration forms (*ceftazidime powder for solution for injection*, *erythrocin*

¹ [Advice on the clustering of combination products and ghost clusters in GVS \(part 1\) | Report | National Health Care Institute \(zorginstituutnederland.nl\)](#)

² [Advice on the clustering of combination products and ghost clusters in GVS \(part 2\) | Report | National Health Care Institute \(zorginstituutnederland.nl\)](#)

³ [Package advice vitamin D | Report | National Health Care Institute \(zorginstituutnederland.nl\)](#)

⁴ [Advice on the clustering of combination products and ghost clusters in GVS \(part 3\) | Report | National Health Care Institute \(zorginstituutnederland.nl\)](#)

powder for intravenous infusion and Haldol® solution for injection). In addition, the National Health Care Institute provides an advisory report on *Sustanon® solution for injection*. This medicinal product has been a ghost drug since October 2022, after the National Health Care Institute advised that *Nebido®*⁵ (reassessment) – which was included in cluster 0G03BAAP V with Sustanon® – could be placed on List 1B.

National Health Care Institute
Care
Medicinal Products

Date
1 March 2023

Our reference
2022048924

Based on the assessments, the National Health Care Institute has completed the following advice: Insuman® Infusat (cartridge), Insuman® Infusat (vial), ceftazidime powder for solution for injection, Insulatard®, Erythrocin® powder for intravenous infusion, Haldol® solution for injection (5 mg/ml) and Sustanon® are not interchangeable with any other medicinal product in the GVS and are therefore eligible for inclusion in List 1B.

Looking ahead: planning for ghost clusters

In this part (part 4) and the previous parts of this feasibility study (parts 1 to 3), the National Health Care Institute advises on various ghost clusters. As explained above, a step-by-step approach has been adopted, with the medicinal products that require a pharmacotherapeutic assessment being dealt with lastly. An overview of ghost products that are still open and may require pharmacotherapeutic assessment can be found in Annex 3. The advisory reports for these products will be issued in 2023 and later. The National Health Care Institute will discuss this matter with you at a later date.

Yours sincerely,

Sjaak Wijma
Chairperson of the Executive Board

Annexes: 3

Annex 1: Substantive discussion of ghost drugs (injections)

Annex 2: Results open consultation

Annex 3: Ghost clusters that have not yet been evaluated by the National Health Care Institute (status in December 2022)

⁵ [GVS advice testosterone undecanoate \(Nebido®\) | Report | National Health Care Institute \(zorginstituutnederland.nl\)](https://www.zorginstituutnederland.nl/publicaties/rapporten/2022/04/28/gvs-advies-testosteron-undecanoaat-(Nebido-®)-rapport)